Latest News RSS

Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease

  PRESS RELEASE Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 - Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a...

Read more →

10-17-2014 UPDATE

10-14

Read more →

BioMarin is currently seeking patients for a Phase 3 clinical trial in Late Onset Pompe Disease.

BioMarin

Read more →

Upcoming Meetings/Events

Coming Soon.

 

 

 

 

 

 

 

 

 

 

 

 

Medical Alert Brochure